DCT

1:26-cv-00222

Janssen Biotech Inc v. Accord Biopharma Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-00222, D. Del., 03/11/2026
  • Venue Allegations: Venue is alleged as proper in the District of Delaware because Defendant Accord Biopharma, Inc. is a Delaware corporation and Defendant Bio-Thera Solutions, Ltd. is a foreign entity subject to suit in any U.S. judicial district.
  • Core Dispute: Plaintiff alleges that Defendants' submission of an Abbreviated Biologics License Application (aBLA) for BAT2506, a proposed biosimilar version of Plaintiff's golimumab products (SIMPONI® and SIMPONI ARIA®), constitutes an act of infringement of seventeen patents covering the antibody, its methods of manufacture, and its methods of use.
  • Technical Context: The technology concerns golimumab, a monoclonal antibody that targets tumor necrosis factor alpha (TNFα), used as a biologic therapeutic for chronic inflammatory diseases like rheumatoid and psoriatic arthritis.
  • Key Procedural History: This action arises under the Biologics Price Competition and Innovation Act (BPCIA) following Defendants' submission of an aBLA to the FDA. The complaint alleges that Defendants failed to comply with their disclosure obligations under the BPCIA's "patent dance" information exchange, which Plaintiff argues provides a basis for the court to facilitate discovery into the accused manufacturing processes.

Case Timeline

Date Event
2007-02-06 Earliest Priority Date for '325 Patent
2009-01-22 Earliest Priority Date for '356 Patent
2011-03-12 Earliest Priority Date for '249 and '410 Patents
2011-07-01 Earliest Priority Date for '889, '858, and '735 Patents
2011-09-13 Issue Date for U.S. Patent No. 8,017,325
2013-03-14 Earliest Priority Date for '830, '168, and '810 (9,487,810) Patents
2013-11-19 Issue Date for U.S. Patent No. 8,586,356
2014-02-20 Earliest Priority Date for '810 (9,663,810) Patent
2014-10-07 Issue Date for U.S. Patent No. 8,852,889
2015-02-17 Issue Date for U.S. Patent No. 8,956,830
2015-10-27 Issue Date for U.S. Patent No. 9,170,249
2015-12-22 Issue Date for U.S. Patent No. 9,217,168
2016-10-25 Issue Date for U.S. Patent No. 9,475,858
2016-11-08 Issue Date for U.S. Patent No. 9,487,810
2017-01-30 Earliest Priority Date for '020 Patent
2017-02-07 Earliest Priority Date for '982 and '566 Patents
2017-05-30 Issue Date for U.S. Patent No. 9,663,810
2018-02-13 Issue Date for U.S. Patent No. 9,890,410
2019-03-14 Earliest Priority Date for '824, '292, and '271 Patents
2021-05-25 Issue Date for U.S. Patent No. 11,014,982
2021-06-22 Issue Date for U.S. Patent No. 11,041,020
2024-10-22 Issue Date for U.S. Patent No. 12,122,824
2024-10-29 Issue Date for U.S. Patent No. 12,129,292
2024-11-12 Issue Date for U.S. Patent No. 12,139,735
2024-12-31 Issue Date for U.S. Patent No. 12,180,271
2025-05-06 Issue Date for U.S. Patent No. 12,291,566
2026-03-11 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,017,325 - "Selection of high-producing cell lines"

The Invention Explained

  • Problem Addressed: The patent addresses the inefficiency and high costs associated with developing commercial-scale manufacturing processes for biologic drugs like antibodies. A critical bottleneck is the selection of cell lines, as it is difficult to quickly and reliably identify which cell clones will be the most productive. '325 Patent, col. 1:49-62
  • The Patented Solution: The invention provides a method to identify high-producing antibody cell lines by measuring the quantity of messenger RNA (mRNA) corresponding to the antibody's heavy chain gene. The patent posits a direct correlation between the amount of heavy chain mRNA and the final yield of the antibody, allowing for a more rapid and predictive screening process compared to methods that rely solely on measuring the final protein product. '325 Patent, abstract '325 Patent, col. 3:56-65 Figure 5A, for example, graphically illustrates the claimed correlation between the heavy chain (HC) gene copy number and the resulting antibody (IgG) production level. '325 Patent, Fig. 5A
  • Technical Importance: This method offers a potential way to accelerate the development timeline for biologic drugs by streamlining the crucial and often lengthy process of cell line selection. '325 Patent, col. 2:24-29

Key Claims at a Glance

  • The complaint asserts infringement of Claim 1, which is the sole independent claim Compl. ¶41
  • The essential elements of Claim 1 are:
    • A method for selecting a cell line for production of antibodies comprising the steps of:
    • a. transfecting an antibody encoding gene, comprising at least a heavy chain gene and, optionally, a light chain gene, into two or more suitable mammalian host cells;
    • b. culturing the transfected host cells;
    • c. quantitating the mRNA encoded by the antibody heavy chain gene in the host cells; and
    • d. selecting the host cell with highest heavy chain gene mRNA quantity.
  • The complaint alleges infringement of one or more claims of the '325 Patent Compl. ¶42

U.S. Patent No. 8,586,356 - "Gal.alpha.1-3gal-containing N-glycans in glycoprotein products derived from CHO cells"

The Invention Explained

  • Problem Addressed: Therapeutic proteins produced in non-human cells, like Chinese Hamster Ovary (CHO) cells, risk being decorated with sugar structures not found in humans. One such structure, galactose-alpha-1,3-galactose ("alpha-gal"), can trigger a significant and potentially harmful immune response in patients, as humans naturally have antibodies against it. '356 Patent, col. 1:16-24
  • The Patented Solution: The patent discloses a method for screening CHO cell lines to ensure they do not produce glycoproteins containing the unwanted alpha-gal structure. The process involves producing the glycoprotein, using enzymes to cleave off its sugar chains (glycans), analyzing those glycans to detect and measure any alpha-gal residues, and selecting only those cell lines that meet a target level (e.g., absence or a very low level) of the residue. '356 Patent, abstract '356 Patent, col. 2:38-55
  • Technical Importance: This invention provides a critical quality control method for ensuring the safety and reducing the immunogenicity of biologic drugs manufactured in CHO cells, a dominant platform in the biopharmaceutical industry. '356 Patent, col. 1:57-61

Key Claims at a Glance

  • The complaint asserts infringement of Claim 1, which is an independent claim Compl. ¶66

  • The essential elements of Claim 1 are:

    • A method for screening Chinese Hamster Ovary (CHO) cells for the ability to produce a target recombinant glycoprotein containing a target level of terminal galactose-alpha-1,3-galactose glycans, the method comprising:
    • (a) producing a target recombinant glycoprotein from CHO cells that have not been genetically engineered to produce the alpha-gal residue;
    • (b) treating the glycans from the glycoprotein with one or more exoglycosidases;
    • (c) detecting the digested alpha-gal residues to measure the amount produced by the CHO cells; and
    • (d) selecting the CHO cells if a target level of the alpha-gal residue is measured.

  • The complaint alleges infringement of one or more claims of the '356 Patent Compl. ¶67

  • Multi-Patent Capsule:

    • Patent Identification: U.S. Patent No. 8,852,889 ("the '889 Patent"), "Cell culture process," issued October 7, 2014 Compl. ¶91
    • Technology Synopsis: The patent is directed to methods of producing a recombinant antibody by culturing a cell in a medium comprising specific concentrations of lysine (1.5 g/L to less than 20 g/L) to control the level of C-terminal variants of the antibody Compl. ¶91 Compl. ¶92
    • Asserted Claims: Claims 1, 6, and 16 are identified as representative independent claims Compl. ¶92
    • Accused Features: The complaint alleges on information and belief that the cell culture media used to manufacture BAT2506 comprises lysine and arginine within the claimed ranges Compl. ¶95

  • Multi-Patent Capsule:

    • Patent Identification: U.S. Patent No. 8,956,830 ("the '830 Patent"), "Methods of cell culture," issued February 17, 2015 Compl. ¶118
    • Technology Synopsis: The patent claims methods of manufacturing a recombinant antibody preparation by culturing cells in a medium containing dimethylsulfoxide (DMSO) to decrease the level of fucosylated glycans or to formulate a drug product with a high level of high mannose glycans Compl. ¶119
    • Asserted Claims: Claims 15 and 37 are identified as representative independent claims Compl. ¶119
    • Accused Features: The complaint alleges on information and belief that the cell culture media for BAT2506 comprises DMSO, resulting in a decreased level of fucosylated glycans and a formulation with a high level of high mannose glycans Compl. ¶124 Compl. ¶127 Compl. ¶132

  • Multi-Patent Capsule:

    • Patent Identification: U.S. Patent No. 9,170,249 ("the '249 Patent"), "N-acetylhexosamine-containing N-glycans in glycoprotein products," issued October 27, 2015 Compl. ¶150
    • Technology Synopsis: The patent relates to methods for manufacturing a glycoprotein preparation by determining the level of a specific N-linked glycan (a single N-acetylhexosamine residue) and then processing the preparation into a pharmaceutical product based on that determination Compl. ¶151
    • Asserted Claims: Claim 1 is identified as a representative independent claim Compl. ¶151
    • Accused Features: The complaint alleges on information and belief that Defendants determine the level of the specified glycan in their BAT2506 preparation and process the product based on that determination Compl. ¶155

  • Multi-Patent Capsule:

    • Patent Identification: U.S. Patent No. 9,217,168 ("the '168 Patent"), "Methods of cell culture," issued December 22, 2015 Compl. ¶173
    • Technology Synopsis: The patent is directed to methods of producing a recombinant protein by culturing cells in a medium containing specific concentrations of putrescine (0.1 mg/L to 10 mg/L) to achieve certain glycan profiles, such as increased galactosylated and sialylated glycans or decreased high mannose glycans Compl. ¶174
    • Asserted Claims: Claims 13 and 16 are identified as representative independent claims Compl. ¶174
    • Accused Features: The complaint alleges on information and belief that the BAT2506 manufacturing process uses a cell culture medium containing putrescine in the claimed range to achieve the claimed glycan profiles Compl. ¶178 Compl. ¶181 Compl. ¶183

  • Multi-Patent Capsule:

    • Patent Identification: U.S. Patent No. 9,475,858 ("the '858 Patent"), "Cell culture process," issued October 25, 2016 Compl. ¶201
    • Technology Synopsis: The patent claims methods of manufacturing a recombinant antibody by culturing a cell in a medium with specific concentrations of lysine (2 g/L to 8 g/L) and/or arginine (2 g/L to 8 g/L) and formulating the product to meet a target value of C-terminal variants Compl. ¶202
    • Asserted Claims: Claims 1 and 20 are identified as representative independent claims Compl. ¶202
    • Accused Features: The complaint alleges on information and belief that the cell culture media used to manufacture BAT2506 comprises lysine and arginine in the claimed concentrations Compl. ¶205

  • Multi-Patent Capsule:

    • Patent Identification: U.S. Patent No. 9,487,810 ("the '810 Patent"), "Methods of cell culture," issued November 8, 2016 Compl. ¶228
    • Technology Synopsis: The patent describes methods of producing a recombinant protein preparation having a target value of high mannose glycans (0.1% to 20%) by culturing cells in a medium comprising dimethylsulfoxide (DMSO) Compl. ¶229
    • Asserted Claims: Claim 1 is identified as a representative independent claim Compl. ¶229
    • Accused Features: The complaint alleges on information and belief that the BAT2506 manufacturing process uses a cell culture medium containing DMSO Compl. ¶234

  • Multi-Patent Capsule:

    • Patent Identification: U.S. Patent No. 9,663,810 ("the '3810 Patent"), "Methods of cell culture," issued May 30, 2017 Compl. ¶256
    • Technology Synopsis: The patent claims methods of producing a recombinant protein preparation with an increased level of fucosylated glycans by culturing cells in a medium containing a specific concentration of putrescine (0.1 mg/L to 10 mg/L) Compl. ¶257
    • Asserted Claims: Claim 14 is identified as a representative independent claim Compl. ¶257
    • Accused Features: The complaint alleges on information and belief that the BAT2506 manufacturing process uses a cell culture medium containing putrescine and results in a preparation with at least 10% higher fucosylated glycans Compl. ¶262 Compl. ¶265

  • Multi-Patent Capsule:

    • Patent Identification: U.S. Patent No. 9,890,410 ("the '410 Patent"), "N-acetylhexosamine-containing N-glycans in glycoprotein products," issued February 13, 2018 Compl. ¶283
    • Technology Synopsis: The patent is directed to methods of manufacturing an antibody preparation by determining the level of an N-linked glycan consisting of a single N-acetylglucosamine residue and processing the antibody into a pharmaceutical product based on that determination Compl. ¶284
    • Asserted Claims: Claim 1 is identified as a representative independent claim Compl. ¶284
    • Accused Features: The complaint alleges on information and belief that Defendants determine the level of the specified N-linked glycan and process the BAT2506 product based on that determination Compl. ¶288

  • Multi-Patent Capsule:

    • Patent Identification: U.S. Patent No. 11,014,982 ("the '982 Patent"), "Anti-TNF antibodies, compositions, and methods for the treatment of active ankylosing spondylitis," issued May 25, 2021 Compl. ¶306
    • Technology Synopsis: The patent claims methods for treating active ankylosing spondylitis by administering an anti-TNF antibody (golimumab) via IV infusion, where treatment results in a specified mean change from baseline in one or more clinical assessment scores Compl. ¶307
    • Asserted Claims: Claims 4 and 7 are identified as representative independent claims Compl. ¶307
    • Accused Features: The complaint alleges Defendants' submission of the aBLA for BAT2506, which will be used to treat ankylosing spondylitis, constitutes infringement Compl. ¶314

  • Multi-Patent Capsule:

    • Patent Identification: U.S. Patent No. 11,041,020 ("the '020 Patent"), "Methods for the treatment of active psoriatic arthritis," issued June 22, 2021 Compl. ¶329
    • Technology Synopsis: The patent claims methods for treating active psoriatic arthritis by administering an anti-TNF antibody (golimumab) via IV infusion, resulting in specific clinical outcomes measured by the van der Heijde-Sharp score or ACR20 response Compl. ¶330
    • Asserted Claims: Claims 4 and 7 are identified as representative independent claims Compl. ¶330
    • Accused Features: The complaint alleges Defendants' submission of the aBLA for BAT2506, which will be used to treat psoriatic arthritis, constitutes infringement Compl. ¶337

  • Multi-Patent Capsule:

    • Patent Identification: U.S. Patent No. 12,122,824 ("the '824 Patent"), "Anti-TNF antibodies, compositions, and methods for the treatment of active ankylosing spondylitis," issued October 22, 2024 Compl. ¶352
    • Technology Synopsis: The patent is directed to methods of treating active psoriatic arthritis by administering an anti-TNF antibody (golimumab) with specific heavy and light chain sequences, via IV infusion at a specific dose and schedule, resulting in a specified clinical outcome Compl. ¶353
    • Asserted Claims: Claims 3 and 5 are identified as representative independent claims Compl. ¶353
    • Accused Features: The complaint alleges Defendants' aBLA submission for BAT2506, intended for treating psoriatic arthritis, constitutes infringement Compl. ¶360

  • Multi-Patent Capsule:

    • Patent Identification: U.S. Patent No. 12,129,292 ("the '292 Patent"), "Anti-tumor necrosis factor (TNF) antibodies compositions thereof," issued October 29, 2024 Compl. ¶375
    • Technology Synopsis: The patent claims anti-TNF antibodies having a specific heavy and light chain amino acid sequence, wherein the oligosaccharide profile comprises a high level of neutral species (>99.0%) and a low level of charged species (<1.0%) Compl. ¶376
    • Asserted Claims: Claim 1 is identified as a representative independent claim Compl. ¶376
    • Accused Features: The complaint alleges on information and belief that the BAT2506 product has the claimed oligosaccharide profile Compl. ¶380

  • Multi-Patent Capsule:

    • Patent Identification: U.S. Patent No. 12,139,735 ("the '735 Patent"), "Cell culture process," issued November 12, 2024 Compl. ¶397
    • Technology Synopsis: The patent claims a preparation of a recombinant antibody having a target level of specific C-terminal lysine variants (K1 and K2), produced by expressing the antibody in a cell culture medium comprising 2 g/L lysine to 20 g/L lysine Compl. ¶398
    • Asserted Claims: Claim 1 is identified as a representative independent claim Compl. ¶398
    • Accused Features: The complaint alleges on information and belief that BAT2506 has the claimed target level of C-terminal variants and is produced in a medium with the claimed lysine concentration Compl. ¶405 Compl. ¶407

  • Multi-Patent Capsule:

    • Patent Identification: U.S. Patent No. 12,180,271 ("the '271 Patent"), "Manufacturing methods for producing anti-TNF antibody compositions," issued December 31, 2024 Compl. ¶424
    • Technology Synopsis: The patent claims anti-TNF antibodies with a specific amino acid sequence and a defined oligosaccharide profile where total neutral species are >99.0% and total charged species are <1.0% Compl. ¶425 This appears to be very similar to the '292 Patent.
    • Asserted Claims: Claim 1 is identified as a representative independent claim Compl. ¶425
    • Accused Features: The complaint alleges on information and belief that BAT2506 has the claimed amino acid sequence and oligosaccharide profile Compl. ¶426 Compl. ¶429

  • Multi-Patent Capsule:

    • Patent Identification: U.S. Patent No. 12,291,566 ("the '566 Patent"), "Anti-TNF antibodies, compositions, and methods for the treatment of active ankylosing spondylitis," issued May 6, 2025 Compl. ¶446
    • Technology Synopsis: The patent is directed to methods of treating active ankylosing spondylitis by administering an IV infusion of an anti-TNF antibody with a specified amino acid sequence and dosing regimen, resulting in defined clinical outcomes Compl. ¶447
    • Asserted Claims: Claims 3 and 5 are identified as representative independent claims Compl. ¶447
    • Accused Features: The complaint alleges Defendants' aBLA submission for BAT2506, intended for treating ankylosing spondylitis, constitutes infringement Compl. ¶454

III. The Accused Instrumentality

Product Identification

  • The accused instrumentality is "BAT2506," a proposed biosimilar copy of Janssen's biologic drugs SIMPONI® and SIMPONI ARIA® Compl. ¶4

Functionality and Market Context

  • BAT2506 is a biologic drug whose active ingredient is golimumab, a human monoclonal antibody that blocks the inflammatory molecule tumor necrosis factor alpha (TNFα) Compl. ¶2 Compl. ¶21 It is intended for the treatment of chronic inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis Compl. ¶2 Defendants Accord and Bio-Thera are seeking regulatory approval from the FDA to market BAT2506 in the United States under the BPCIA's abbreviated pathway for biosimilars Compl. ¶4 Compl. ¶24 The complaint notes that Janssen's own golimumab products achieved U.S. sales exceeding $1 billion in 2024, highlighting the significant market value of the therapy Defendants seek to copy Compl. ¶19

IV. Analysis of Infringement Allegations

No probative visual evidence provided in complaint.

U.S. Patent No. 8,017,325 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
a. transfecting an antibody encoding gene... into two or more suitable mammalian host cells; The manufacture of BAT2506 is alleged to involve introducing genes for the golimumab antibody into mammalian host cells. ¶42 col. 3:6-9
b. culturing the transfected host cells; The manufacture of BAT2506 is alleged to involve culturing the genetically modified cells to produce the antibody. ¶42 col. 5:10-12
c. quantitating the mRNA encoded by the antibody heavy chain gene in the host cells; On information and belief, Defendants' cell line selection process for manufacturing BAT2506 involves measuring the heavy chain mRNA quantity in the host cells. ¶47 col. 6:4-9
d. selecting the host cell with highest heavy chain gene mRNA quantity. On information and belief, Defendants select the cell line for manufacturing based on it having the highest heavy chain mRNA quantity. ¶47 col. 6:10-12
  • Identified Points of Contention:
    • Evidentiary Questions: The complaint's allegations regarding the core inventive steps (c and d) are made "on information and belief" Compl. ¶47 Plaintiff states it has been denied access to the details of the cell line selection process Compl. ¶48 A central question for the court will be whether discovery reveals evidence that Defendants' process for selecting their manufacturing cell line actually involves quantitating heavy chain mRNA and selecting the cell line with the "highest" quantity, as the claim requires.
    • Scope Questions: The term "selecting the host cell with highest... mRNA quantity" may become a point of contention. The question may arise whether this requires a strict, rank-ordered selection based solely on this metric, or if it can cover a more holistic process where mRNA quantity is one of several important, or even decisive, factors.

U.S. Patent No. 8,586,356 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
(a) producing a target recombinant glycoprotein... by culturing CHO cells... wherein the CHO cells have not been genetically engineered to produce terminal alpha-galactosyl residues... The manufacture of BAT2506 is alleged to involve producing the golimumab glycoprotein in CHO cells that are not engineered to produce alpha-gal residues. ¶67 col. 2:38-43
(b) treating the one or more glycans of the target recombinant glycoprotein with one or more exoglycosidases; On information and belief, Defendants' process involves treating the glycans from the produced golimumab with enzymes. ¶70 col. 2:43-44
(c) detecting digested terminal galactose-alpha-1-3-galactose residues... On information and belief, Defendants detect for the presence of alpha-gal residues as part of their manufacturing or screening process. ¶73 col. 2:45-49
(d) selecting the CHO cells if a target level of terminal galactose-alpha-1-3-galactose residues is measured. On information and belief, Defendants select their CHO cells for manufacturing based on a measurement of the level of alpha-gal residues. ¶73 col. 2:50-52
  • Identified Points of Contention:
    • Evidentiary Questions: As with the '325 Patent, the allegations are based "on information and belief," and Plaintiff notes Defendants' failure to provide complete manufacturing information Compl. ¶70 Compl. ¶71 The case will depend on whether Plaintiff can prove through discovery that Defendants' process actually includes the specific enzymatic treatment and detection steps for alpha-gal residues as claimed.
    • Technical Questions: A key question will be whether the accused activities constitute a "method for screening... cells" as recited in the claim's preamble. Defendants may argue that their process, if it includes any such steps, is for routine lot-release quality control of a finished product, not for the initial "screening" and selection of a cell line from a population of candidates, potentially placing their activities outside the scope of the claim.

V. Key Claim Terms for Construction

  • Patent: U.S. Patent No. 8,017,325
  • The Term: "selecting the host cell with highest heavy chain gene mRNA quantity"
  • Context and Importance: This term defines the central inventive step of the claimed method. The infringement analysis will hinge on whether Defendants' cell selection process, which is currently unknown to Plaintiff, meets this specific, superlative criterion. Practitioners may focus on this term because it is the dispositive step that distinguishes the invention from prior art methods.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: Plaintiff may argue the term encompasses any selection process where the heavy chain mRNA level is used as the determinative factor for identifying the most productive clone. The patent's summary describes the invention as a method of selecting a cell based on its "highest heavy chain gene mRNA quantity," which could be interpreted as the primary basis for selection among candidates. '325 Patent, abstract
    • Evidence for a Narrower Interpretation: Defendant may argue that the plain language "highest" requires a direct, rank-ordered comparison of mRNA levels among a pool of cells, with the top-ranked cell being chosen. Language in the patent states the invention is a method of "predicting" productivity, and Figure 5A shows a correlation, not a perfect one-to-one relationship, which may suggest that selecting for the "highest" mRNA level is a specific implementation, not a general principle. '325 Patent, col. 4:20-24 '325 Patent, Fig. 5A
  • Patent: U.S. Patent No. 8,586,356
  • The Term: "method for screening"
  • Context and Importance: This term, found in the preamble of Claim 1, sets the context for the claimed steps. Its interpretation is critical because Defendants' alleged infringement occurs in the context of commercial manufacturing, and they may argue their activities are for "quality control," not "screening." The distinction could be case-dispositive.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: Plaintiff may point to language stating the invention provides "methods for evaluating CHO cells" and monitoring for "the potential for adverse reactions," suggesting a broad purpose that could include ongoing quality control throughout the manufacturing lifecycle. '356 Patent, col. 1:25-26 '356 Patent, col. 1:59-61
    • Evidence for a Narrower Interpretation: Defendant may argue that "screening" is a term of art referring to the initial research and development phase of selecting a single lead cell line from many candidates. The patent's description of screening "a population of CHO cell preparations" to "identify a suitable cell line" for a therapeutic glycoprotein supports this interpretation of an upfront, one-time selection process rather than a recurring manufacturing check. '356 Patent, col. 2:50-55

VI. Other Allegations

  • Indirect Infringement: For the asserted method-of-treatment patents (e.g., the '982 and '020 patents), the complaint alleges that Defendants will indirectly infringe. It claims Defendants will actively induce infringement by physicians and patients who will use BAT2506 according to its label and instructions, which will allegedly direct them to perform the patented treatment methods Compl. ¶320 Compl. ¶343
  • Willful Infringement: The complaint alleges willful infringement for all asserted patents. The basis for willfulness is that Defendants have have knowledge of the patents and their relevance to BAT2506 since at least the time Janssen provided its list of patents under the BPCIA process, as well as through the filing of the complaint itself Compl. ¶50 Compl. ¶76 The complaint alleges that Defendants' continued actions toward marketing BAT2506, despite this knowledge, constitute deliberate and intentional disregard for Janssen's patent rights Compl. ¶51 Compl. ¶77

VII. Analyst's Conclusion: Key Questions for the Case

  • The Evidentiary Hurdle of BPCIA Litigation: A central issue will be one of evidentiary proof. The complaint is replete with allegations made "on information and belief" regarding Defendants' secret manufacturing processes. The case's viability will depend on whether discovery, potentially compelled by the court due to Defendants' alleged failure to fully engage in the BPCIA "patent dance," uncovers facts showing that the BAT2506 manufacturing process actually uses the specific steps claimed in Janssen's numerous process patents.
  • Process Characterization and Claim Scope: The litigation will likely feature a significant dispute over claim construction and process characterization. Specifically, for patents like the '356 Patent, a key question for the court will be whether routine quality control steps performed during commercial manufacturing fall within the scope of a claim directed to a "method for screening" cells, a term that may be interpreted as being limited to the initial research and development phase.
  • Induced Infringement via Product Label: For the portfolio of method-of-treatment patents, the core question will be one of induced infringement. The analysis will focus on whether the proposed label for BAT2506 will instruct or encourage medical professionals to administer the drug in a manner that directly practices the specific dosing regimens and achieves the clinical outcomes recited in claims of patents like the '982 and '020 patents.
Loading Complaint